Search research articles
Contact Us
Filters
Showing results (51-60 of 82) with videos related to
Page
of 9
Sort By:
The European Respiratory Journal
|
February 5, 2021
Optimising pyrazinamide for the treatment of tuberculosis
Nan Zhang, Radojka M Savic, Martin J Boeree, et al.
The Lancet. Microbe
|
May 12, 2024
Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles
Stephen H Gillespie, Andrew R DiNardo, Sophia B Georghiou, et al.
Tropical Medicine & International Health : TM & IH
|
March 8, 2021
Molecular epidemiology of respiratory syncytial virus in children in sub-Saharan Africa
Clara Marlene Ihling, Paul Schnitzler, Norbert Heinrich, et al.
Plos Medicine
|
September 16, 2024
HIV, malnutrition, and noncommunicable disease epidemics among tuberculosis-affected households in east and southern Africa: A cross-sectional analysis of the ERASE-TB cohort
Claire Jacqueline Calderwood, Edson Tawanda Marambire, Leyla Larsson, et al.
PLOS Global Public Health
|
April 30, 2026
Refining research outcomes: Lessons from the setup of an endpoint review committee and radiological review in tuberculosis observational diagnostic studies
Leyla Larsson, Claire J Calderwood, Edson T Marambire, et al.
Tropical Medicine & International Health : TM & IH
|
September 11, 2022
The second national anti-tuberculosis drug resistance survey in Tanzania, 2017-2018
Beatrice Kemilembe Mutayoba, Julia Ershova, Eligius Lyamuya, et al.
Frontiers in Microbiology
|
October 26, 2020
Regional Variation of Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacterales, Fluoroquinolone-Resistant <i>Salmonella enterica</i> and Methicillin-Resistant <i>Staphylococcus aureus</i> Among Febrile Patients in Sub-Saharan Africa
Rehema Moraa Moirongo, Eva Lorenz, Nyanda E Ntinginya, et al.
Frontiers in Antibiotics
|
March 18, 2026
Correction: Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials
Andrew R DiNardo, Wilbert Sabiiti, Stephen H Gillespie, et al.
The Lancet. Global Health
|
February 19, 2026
Characterising progression and regression patterns across the spectrum of tuberculosis: a multistate modelling approach
Leyla Larsson, Claire J Calderwood, Edson T Marambire, et al.
The Lancet. Respiratory Medicine
|
January 17, 2014
Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment
Sven O Friedrich, Andrea Rachow, Elmar Saathoff, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 82) with videos related to
Sort By:
Page
of 9
The European Respiratory Journal
|
February 5, 2021
Optimising pyrazinamide for the treatment of tuberculosis
Nan Zhang, Radojka M Savic, Martin J Boeree, et al.
The Lancet. Microbe
|
May 12, 2024
Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles
Stephen H Gillespie, Andrew R DiNardo, Sophia B Georghiou, et al.
Tropical Medicine & International Health : TM & IH
|
March 8, 2021
Molecular epidemiology of respiratory syncytial virus in children in sub-Saharan Africa
Clara Marlene Ihling, Paul Schnitzler, Norbert Heinrich, et al.
Plos Medicine
|
September 16, 2024
HIV, malnutrition, and noncommunicable disease epidemics among tuberculosis-affected households in east and southern Africa: A cross-sectional analysis of the ERASE-TB cohort
Claire Jacqueline Calderwood, Edson Tawanda Marambire, Leyla Larsson, et al.
PLOS Global Public Health
|
April 30, 2026
Refining research outcomes: Lessons from the setup of an endpoint review committee and radiological review in tuberculosis observational diagnostic studies
Leyla Larsson, Claire J Calderwood, Edson T Marambire, et al.
Tropical Medicine & International Health : TM & IH
|
September 11, 2022
The second national anti-tuberculosis drug resistance survey in Tanzania, 2017-2018
Beatrice Kemilembe Mutayoba, Julia Ershova, Eligius Lyamuya, et al.
Frontiers in Microbiology
|
October 26, 2020
Regional Variation of Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacterales, Fluoroquinolone-Resistant <i>Salmonella enterica</i> and Methicillin-Resistant <i>Staphylococcus aureus</i> Among Febrile Patients in Sub-Saharan Africa
Rehema Moraa Moirongo, Eva Lorenz, Nyanda E Ntinginya, et al.
Frontiers in Antibiotics
|
March 18, 2026
Correction: Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials
Andrew R DiNardo, Wilbert Sabiiti, Stephen H Gillespie, et al.
The Lancet. Global Health
|
February 19, 2026
Characterising progression and regression patterns across the spectrum of tuberculosis: a multistate modelling approach
Leyla Larsson, Claire J Calderwood, Edson T Marambire, et al.
The Lancet. Respiratory Medicine
|
January 17, 2014
Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment
Sven O Friedrich, Andrea Rachow, Elmar Saathoff, et al.
Page
of 9